Edition:
United States

Genocea Biosciences Inc (GNCA.OQ)

GNCA.OQ on NASDAQ Stock Exchange Global Market

1.21USD
22 Nov 2017
Change (% chg)

$0.05 (+4.31%)
Prev Close
$1.16
Open
$1.15
Day's High
$1.27
Day's Low
$1.12
Volume
143,685
Avg. Vol
173,661
52-wk High
$7.28
52-wk Low
$1.04

Chart for

About

Genocea Biosciences, Inc., is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company has one... (more)

Overall

Beta: 1.88
Market Cap(Mil.): $34.73
Shares Outstanding(Mil.): 28.70
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 189.94 15.47
EPS (TTM): -- -- --
ROI: -- -10.73 11.81
ROE: -- -36.69 15.76

BRIEF-Genocea Biosciences inc qtrly ‍loss per share $0.59​

* Genocea biosciences - ‍expects existing cash and cash equivalents sufficient to support operating expenses and capital expenditure into middle of 2018​

Nov 02 2017

BRIEF-Genocea announces strategic shift to immuno-oncology and the development of neoantigen cancer vaccines

* Genocea announces strategic shift to immuno-oncology and the development of neoantigen cancer vaccines

Sep 25 2017

BRIEF-Genocea Biosciences reports qtrly loss per share $‍0.54​

* Genocea Biosciences reports second quarter 2017 financial results

Aug 09 2017

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF83.60 +0.30
Pfizer Inc. (PFE.N) $35.43 -0.11
Merck & Co., Inc. (MRK.N) $54.37 +0.10
Sanofi SA (SASY.PA) €77.54 +0.83
AstraZeneca plc (AZN.L) 4,999.50 -7.50
GlaxoSmithKline plc (GSK.L) 1,305.50 +3.00
Vical Incorporated (VICL.OQ) $1.87 -0.03

Earnings vs. Estimates